Addressing the Economic and Operational Issues of the Clinical Practice Gaps in NSCLC
This paper outlines the 5 critical recommendations developed by The Health and Economic Forum to provide industry and policy makers with valuable and clear economic guidance and recommendations to overcome the challenges obstructing the advancement of precision medicine.
About the Paper
Background
In August 2023, an interdisciplinary group of experts, known as ‘The Precision Medicine Practice Gaps Economic, Policy and Operational Solutions Forum’ was established to urgently address the economic and operational barriers currently preventing 64.4% of patients gaining access to the optimal precision medicine treatment for them, as identified in Diaceutics’ widely cited Clinical Practice Gaps paper published JCO in 2022.
The Summit
The solutions and recommendations proposed by the Forum were shared and opened for discussion at a virtual global summit earlier this year, broadcast from Diaceutics’ headquarters in Belfast. The Summit attracted over 400 registrants from various sectors, including pharmaceuticals, academia, clinical research, diagnostic labs, payers, policy, and patient advocacy groups. Following the Summit, the Forum refined these recommendations into clear, actionable guidelines. These final recommendations, presented in this white paper, aim to provide industry and policy makers with valuable and clear economic guidance and recommendations to overcome the challenges obstructing the advancement of precision medicine.
The Forum Members
Authors
Susanne Munskted¹, Denny Van Liew², Daryl Pritchard³, Jayeta Saxena¹, Mark Lawler⁴, Sarah Hersey⁵, Cecilia Schott⁶, Pranil Chandra⁷, Dawn Cardeiro⁸, Brenda Yanak⁹, Terri Conneran¹⁰, Amy S. Gorman¹¹, Kamala K. Maddali¹², Gerardine Doyle¹³, Sibylle Lenz¹⁴, Peter Keeling¹
1. Diaceutics PLC, 2. Pareto Group, 3. Personalized Medicine Coalition, 4. Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, 5. Bristol-Myers Squibb 6. GlaxoSmithKline, 7. PathGroup, 8. Point32Health, 9. Clinical Transformation Partners, 10. KRAS KickersWatch the full Summit recording
You might also be interested in?
Rethinking Drug Commercialization: Navigating a Shifting Biotech Investment Landscape
Explore strategies for biotech commercialization amid evolving investment landscapes, focusing on precision and rare disease therapies. Join industry experts in navigating funding challenges and enhancing patient outcomes.